seekingalpha.com
CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CG Oncology, Inc. (CGON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CG Oncology, Inc. Common stockCGONNASDAQ
LOADING
|||
Latest News
zacks.com
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites.
seekingalpha.com
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene
CG Oncology maintains a "Strong Buy" rating, driven by significant pipeline progress and multiple upcoming catalysts in 2026. Completion of the rolling BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC and potential FDA acceptance are key near-term catalysts in 2026. Early enrollment completion in the phase 3 PIVOT-006 trial for IR-NMIBC accelerates topline data to 1H 2026, positioning the company for a potential first FDA approval in this segment.
globenewswire.com
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule
globenewswire.com
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:15 am PT / 11:15 am ET. The conference is taking place at the Westin St. Francis San Francisco, California.
seekingalpha.com
CG Oncology Undervalued Going Into A Busy 2026
CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities.
defenseworld.net
CG Oncology (NASDAQ:CGON) Reaches New 1-Year High – What’s Next?
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) shares reached a new 52-week high during trading on Friday. The company traded as high as $46.01 and last traded at $44.84, with a volume of 98696 shares changing hands. The stock had previously closed at $44.73. Analysts Set New Price Targets Several equities research analysts
globenewswire.com
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A which demonstrated promising efficacy, safety and tolerability. These data will be presented today as Late-Breaking Abstracts at the Society of Urologic Oncology (SUO) 26th Annual Meeting.
globenewswire.com
CG Oncology Announces New Board Member and Board Transition
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the appointment of Christina Rossi to its Board of Directors.
zacks.com
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago.
globenewswire.com
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2025, and provided business updates.
defenseworld.net
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of “Moderate Buy” by Brokerages
Shares of CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have assigned a buy recommendation and
seekingalpha.com
CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?
CG Oncology remains a compelling buy, driven by strong phase 3 data for its oncolytic virus therapy in bladder cancer. CGON's lead candidate, cretostimogene grenadenorepvec, achieved a 41.8% complete response rate at 24 months in high-risk NMIBC patients. CGON boasts a robust cash runway, supporting ongoing trials and potential regulatory delays, but FDA approval is not guaranteed and competition is intensifying.
fool.com
Why Cg Oncology Stock Rocketed 7% Higher Today
Highly specialized biotech CG Oncology (CGON 7.13%) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the day, easily beating the 0.6% advance of the bellwether S&P 500 (^GSPC 0.58%).
zacks.com
CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last?
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
seekingalpha.com
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
CG Oncology, Inc. (NASDAQ:CGON ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Arthur Kuan - Chairman & CEO Ambaw Bellete - President & COO Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Okay. Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference.
globenewswire.com
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment -- 90% of 12-month responders remained disease free at 24 Months -- Safety profile remains consistent -
globenewswire.com
CG Oncology Completes Enrollment in PIVOT-006
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines –
https://thefly.com
CG Oncology initiated with an Overweight at Piper Sandler
Piper Sandler analyst Kelsey Goodwin initiated coverage of CG Oncology with an Overweight rating and $55 price target. The stock currently reflects low uptake in the initial high-risk Bacillus Calmette-Guerin nonmuscle invasive bladder cancer setting, and no value for label extensions, despite multiple shots on goal in additional NMIBC settings coming later this year, the analyst tells investors in a research note. 13 Dec